2015 Winner Profile

Eli Lilly and Co.

Project Description:
One critical activity in the biopharmaceutical discovery process is taking a newly discovered chemical or biological compound that shows some efficacy and changing its structure to improve its properties. This process, in the past, had taken weeks and required expert-mediated tools requiring close oversight. Eli Lilly and Co.'s goal was to shorten this process by creating the Multi-Dimensional Drug Designer (MD3). MD3 integrates multiple informatics components into a single application with an intuitive interface, puts compound design tools into the hands of medicinal chemists, increasing their effectiveness in the early stages of the drug discovery process. The improvement has resulted in fewer molecules synthesized per drug discovery project, resulting in cost savings of several thousand dollars for each compound not synthesized. Using MD3, Lilly has reduced the process time for in silico modeling from weeks to hours and evaluated more than 7 million virtual molecules in 2014.
Project type:
Business Intelligence or Data Analytics
Business Functions:
Research and Development
Business Goal:
Strategic Impact or Competitive Advantage
Ina Kamenz, SVP & CIO
John Lechleiter, Chairman, President & CEO
Indianapolis, Ind.
Revenue (2014):
$19.62 billion
View All 2015 Winners »